Joshua Swan

About Joshua Swan

Strategic medical leader with 15+ years of experience across pharmaceutical R&D, global clinical development, and translational research. As a Senior Director at Pfizer, I lead global Phase 2 and 3 programs in obesity and metabolic disease, including an oral GLP-1 receptor agonist.I bring deep expertise in clinical development planning, regulatory engagement (FDA, EMA), and real-world evidence (RWE) strategy. Formerly a clinical scientist and educator, I’ve authored 40+ peer-reviewed publications and led health system-wide changes in formulary and access strategy.Passionate about advancing science that improves patient lives through innovation, evidence, and cross-functional collaboration.

Experience

1. Senior Director, Global Development Lead, Obesity Franchise

   Pfizer

   Mar 2026 — Present

   Represents Clinical on the Global Medicine Team as the single clinical point of accountability for clinical development for assigned asset(s) in the Obesity Franchise.• Accountable for creating and gaining endorsement for the Clinical Development Plan for assigned asset(s) in the Obesity Franchise.• Lead Clinical efforts on regulatory submissions for assigned asset(s) in the Obesity Franchise.• Author protocols for global Phase 2 and Phase 3 studies for assigned asset(s) in the Obesity Franchise.

Education

• UTHealth Houston

  Master of Public Health (MPH), Epidemiology

  2014 — 2016

• University of Mississippi

  BS, Cum Laude, Pharmacy

  2003 — 2007

• University of Mississippi

  Pharm.D., Pharmacy

  2007 — 2009

Skills

• Healthcare Information Technology
• Critical Care
• Clinical Pharmacy
• Hospitals
• Pharmacists
• Pharmacy Practice
• Pharmacy
• Healthcare
• Research
• Clinical Research
• Critical Care Medicine